Nurix Therapeutics
NX-5948 is a CNS-penetrant catalytic BTK degrader that breaks established design rules for CNS drugs, opening B-cell malignancies with CNS involvement.
- Country
- United States
- Ticker
- NRIX
BTK degrader (NX-5948)
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| PROTACs (targeted protein degradation) | therapeutics-platforms | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.